Skip to main content
Premium Trial:

Request an Annual Quote

Genset and Algene Sign Alzheimer's Study Alliance


PARIS--Genset and Algene Biotechnologies of Montreal have formed a strategic alliance for research into Alzheimer's disease. Algene has amassed a collection of clinical samples from Alzheimer's patients in Quebec and, by applying its gene mapping and statistical analysis platforms to these samples, has identified several chromosomal regions suspected to contain genes associated with the disease.

Algene will license its proprietary gene mapping results and provide access to its existing Alzheimer's disease DNA collections exclusively to Genset. In turn, Genset will use its genomics technologies to generate proprietary markers, perform high-throughput genotyping of the samples, and apply its biostatistics and bioinformatics tools to analyze the resulting association data. Genset will also fund a one-year research program at Algene for further sample collection.

Filed under

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.